1. Introductions
================

Diabetes affects \>400 million subjects worldwide.^\[[@R1]\]^ Prediabetes was defined as participants who did not meet the criteria of diabetes but who had impaired fasting glucose or impaired glucose tolerance.^\[[@R2]\]^ It is estimated that 374 million adults had prediabetes worldwide in 2017 (prevalence 7.7%) by the International Diabetes Federation (IDF).^\[[@R3]\]^ Populations with prediabetes are at a 50% higher risk of developing type 2 diabetes.^\[[@R4]\]^ Diabetes mellitus is associated with several vascular and nonvascular complications such as stroke, heart disease, and nerve damages.^\[[@R5]\]^ Thus, it is essential to prevent the progression of prediabetes to diabetes.

Some meta-analyses indicated significant associations between vitamin D and diabetes. A recent meta-analysis indicated that hypovitaminosis D is associated with an elevated risk of future diabetes in old adults.^\[[@R6]\]^ Additionally, a meta-analysis showed a reduction of hemoglobin A~1c~ (HbA~1c~) after vitamin D treatment in adults with type 2 diabetes.^\[[@R7]\]^ However, the studies showed conflicting results regarding the associations between vitamin D and prediabetes. Some studies indicated that individuals with prediabetes showed lower serum 25-hydroxy (OH) vitamin D concentrations compared with those with normal controls.^\[[@R8],[@R9]\]^ Additionally, individuals with prediabetes who are vitamin D deficient showed greater risk of developing diabetes.^\[[@R10]\]^ Moreover, some randomized controlled trials (RCTs) explored the clinical benefit of vitamin D treatment in patients with prediabetes.^\[[@R11],[@R12]\]^ However, Sollid et al^\[[@R12]\]^ reported that vitamin D supplementation does not improve glycemic indices in prediabetes patients. A systematic review and meta-analysis is essential to summary these inconsistent results. The present study aimed to make a systematic review and meta-analysis for the association between vitamin D and prediabetes.

2. Methods
==========

We performed a meta-analysis according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guideline^\[[@R13]\]^ to explore the associations between vitamin D and prediabetes. The study is a meta-analysis, an analysis with secondary processing. Thus, ethical approval was not necessary in the study.

2.1. Search strategy and selection criteria
-------------------------------------------

We searched for articles published in English until July 2019 in following databases (PubMed, Web of Science, EMBASE, Medline, Google Scholar, and Cochrane databases). We used following search terms: ("vitamin D" OR "vitamin D3" OR "cholecalciferol" OR "25(OH)D") AND ("prediabetes" OR "insulin resistance" OR "hyperglycemia" OR "HbA1~c~" OR "glucose"). One thousand five hundred twelve studies were included after eliminating duplicates. Included studies explored the associations between vitamin D and prediabetes. Prediabetes was diagnosed by showing HbA1~c~ measured in the range of 5.8% to 6.4%. For the association between serum levels of vitamin D and risks of prediabetes, we included cohort and case--control studies, reporting relative risk (RR) or odds ratio (OR) and 95% confidence intervals (CI) related to vitamin D and risks of prediabetes. Additionally, to explore the therapeutic effects of vitamin D supplementation on prediabetes, we included RCTs comparing outcomes of individuals with prediabetes treated with vitamin D supplementation and placebo. Moreover, we excluded secondary processing articles (meta-analyses and reviews) and case studies. All the abstracts and full texts were read independently by 2 researchers (LY and YZ). When the inconsistencies in the study selection appeared, the articles were discussed and decided by the 3 authors (LY, YZ, and SS).

2.2. Data extraction
--------------------

Two reviewers (LY and YZ) independently used an Excel file to abstract the following data: author, publication year, study type, study location, numbers of participants, information of included participants (age and sex), mean serum levels of 25(OH) vitamin D, follow up time, endpoints, comparison, the ORs or RRs, and 95% CIs after multivariate adjustions, adjusted variables, serum levels of 25(OH) vitamin D at baseline, dose of vitamin D supplementation, duration of trial, outcomes of RCTs.

2.3. Meta-analysis
------------------

In the study, we used *Q* test and *I*^2^ to examine heterogeneities between included studies. Random effects models were performed as pooling methods with invariably high heterogeneity (*P* value for *Q* test ≤.05 and *I*^2^ ≥ 50%); otherwise, fixed effects models were conducted as pooling methods with invariably low heterogeneity (*P* value for *Q* test \>.05 and *I*^2^ \< 50%). Outcomes with an *I*^2^ of 25% to 50% were considered to have low heterogeneity, an *I*^2^ of 50% to 75% was considered as moderate heterogeneity, and an *I*^2^ of \>75% demonstrated high heterogeneity.^\[[@R14]\]^ To explore source of the heterogeneity, we performed meta-regression analyses. Additionally, sensitivity analysis was conducted to evaluate the stabilization of the study. Publication bias was evaluated with Begg test, Egger test, and funnel plot. We conducted these analyses using STATA 12.0 software (Stata Corporation, College Station, TX, USA).

3. Results
==========

3.1. Study selection and characteristics
----------------------------------------

Figure [1](#F1){ref-type="fig"} illustrated the search results and selection process. After eliminating duplicates, 1512 studies were remained. After screening according to titles and abstracts, 30 articles retained for further assessment. We excluded 18 articles because of the following reasons: studies which not included control group or between-group comparisons were excluded (n = 12); Studies with insufficient information were excluded (n = 6). The characteristics of 12 finally included studies were showed in supplementary tables 1 and 2. To explore the association between serum levels of 25(OH) vitamin D and risks of prediabetes, the present study included 1 cohort study (including 490 participants),^\[[@R15]\]^ 3 case--control study (including 2604 participants).^\[[@R8],[@R16],[@R17]\]^ Additionally, the present study included 8 studies (including 865 individuals with prediabetes treated with vitamin D supplementation and 715 patients treated with placebo) to assess differences in therapeutic effects between individuals with prediabetes treated with vitamin D supplementation and those treated with placebo.
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3.2. Results of meta-analysis
-----------------------------

The present study showed that the low serum levels of 25(OH) vitamin D is significantly associated with high risk of prediabetes (OR/RR = 1.54, 95% CI 1.26--1.89, *I*^2^ = 48.9%, *P* = .118, Fig. [2](#F2){ref-type="fig"}). In addition, the study showed no significant differences in changes of HbA~1c~, fasting plasma glucose (FPG) and homeostatic model assessment of insulin resistance (HOMA-IR) between individuals with prediabetes treated with vitamin D and those patients given placebo (HbA~1c~: standardized mean difference \[SMD\] = 0.01, 95% CI --1.08 to 1.10, *I*^2^ = 98.8%, *P* \< .001, Fig. [3](#F3){ref-type="fig"}; FPG: SMD = 1.23, 95% CI --1.05 to 3.51, *I*^2^ = 99.2%, *P* \< .001, Fig. [4](#F4){ref-type="fig"}; HOMA-IR: SMD = 0.81, 95% CI --2.92 to 4.55, *I*^2^ = 99.6%, *P* \< .001, Fig. [5](#F5){ref-type="fig"}), whereas meta-analysis showed significantly greater changes in plasma glucose after 2-hour oral glucose tolerance test (2HPG) in individuals with prediabetes treated with vitamin D, compared with individuals with prediabetes treated with placebo (SMD = 1.80, 95% CI 0.29--3.31, *I*^2^ = 98.6%, *P* \< .001, Fig. [6](#F6){ref-type="fig"}). Meta-regression analysis showed that ages, serum levels of 25(OH) vitamin D at baseline, doses of vitamin D and follow-up durations were not responsible for heterogeneity across studies, serum levels of 25(OH) vitamin D at baseline, doses of vitamin D, and follow-up durations (all *P* \> .05, supplementary table 3). Sensitivity analysis showed no changes in the direction of effect when any one study was excluded in the meta-analyses (Supplementary figure 1). In addition, Begg test, Egger tests, and funnel plots indicated no significant risks of publication bias for these meta-analyses (supplementary table 4 and supplementary figure 2).
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4. Discussion
=============

The present study showed significant associations between low serum levels of 25(OH) vitamin D and high risk of prediabetes. Additionally, the study showed no significant differences in changes of HbA~1c~, FPG, and HOMA-IR between individuals with prediabetes treated with vitamin D and those patients given placebo, whereas meta-analysis showed significantly greater changes in 2HPG in individuals with prediabetes treated with vitamin D, compared with individuals with prediabetes treated with placebo.

Some studies showed that the prevalence of metabolic syndrome, central obesity, hyperglycemia, and hypertension were higher in the vitamin D deficient group.^\[[@R18]\]^ However, the effect of vitamin D supplementation against the progression of diabetes has been reported in several trials with mixed results.^\[[@R19],[@R20]\]^ Our study showed significant associations between low serum levels of 25(OH) vitamin D and high risk of prediabetes.

Additionally, the study showed no significant differences in changes of HbA~1c~, FPG, and HOMA-IR between individuals with prediabetes treated with vitamin D and those patients given placebo, whereas meta-analysis showed significantly greater changes in 2HPG in individuals with prediabetes treated with vitamin D, compared with individuals with prediabetes treated with placebo. Vitamin D supplementation improved glucose metabolism, and glycemic control (2HPG), but failed to improve insulin sensitivity (HOMA-IR) in prediabetes. A recent meta-analysis showed that vitamin D supplementation improved glycemic measures and insulin sensitivity and might be useful as part of a preventive strategy for type 2 diabetes.^\[[@R21]\]^ However, the recent meta-analysis^\[[@R21]\]^ included adults at risk for type 2 diabetes, including prediabetes, overweight, or obesity. Additionally, unlike several studies including known diabetes, our study was performed on the patients with prediabetes. The greatest benefits were found in populations most at risk for early disease.

Our meta-regression analysis showed that ages, serum levels of 25(OH) vitamin D at baseline, doses of vitamin D, and follow-up durations were not responsible for heterogeneity across studies. It is important to note that vitamin D supplementation may play a role in the prevention of type 2 diabetes in high-risk populations, however, type 2 diabetes is a multifactorial disease. Larger studies are needed to further evaluate the glycemic effects of vitamin D treatment especially in patients with vitamin D deficiency.

Some limitations were showed in the present study. Firstly, regarding the associations between serum levels of 25(OH) vitamin D and risks of prediabetes, there were a limited number of studies, potentially limiting statistical power. More large-scale studies might be performed to explore the associations between serum levels of 25(OH) vitamin D and risks of prediabetes. Secondly, regarding the clinical benefit of vitamin D treatment in patients with prediabetes, the amount of included studies was limited to explore the sources of heterogeneities.

5. Conclusions
==============

In conclusion, the study supported that low serum levels of 25(OH) vitamin D increased the risk of prediabetes. In addition, vitamin D supplementation improves impaired glucose tolerance in prediabetes. However, more large-scale clinical trials are essential to explore the association between vitamin D and prediabetes (Supplementary references).
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Abbreviations: 25(OH) vitamin D = 25-hydroxy (OH) vitamin D, 2HPG = 2-hour oral glucose tolerance test, CI = confidence intervals, FPG = fasting plasma glucose, HbA~1c~ = hemoglobin A~1c~, HOMA-IR = homeostatic model assessment of insulin resistance, OR = odds ratio, PRISMA = Preferred Reporting Items for Systematic reviews and Meta-Analysis, RCTs = randomized controlled trials, RR = relative risk, SMD = standardized mean difference.
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